Supporting pharma’s new medicines: Faster launch at lower cost
C2-Ai helps pharma companies target and launch drugs faster, and do so at lower cost
C2-Ai’s systems, built on 30 years research and the World’s largest patient dataset, can help Pharma companies deliver target and then deliver new drugs to market more quickly and at lower cost.
We can deliver insights, direction and feedback on unmet needs using the largest referential patient dataset in the world (200m episodes of care from 46 countries) and then support more efficient development processes.
Drug trials today will typically exclude patients with comorbidities because it is too complicated to isolate the effect of these from the impact on the patient of a trial drug or treatment.
C2-Ai’s systems manage this complexity by risk-adjusting for a patient’s physiology/comorbidities to calculate the resultant probability of complications by type and risk of mortality.
This risk-adjustment eliminates the ‘noise’ and complexity due to the variation between patients. Comparing the observed patient outcomes with the expected outcomes across a site therefore allows meaningful insights into the efficacy or otherwise of a treatment being trialled.
At the same time, this methodology should permit enrolment of greater numbers of patients as inclusion criteria can be broadened to reflect robust analysis of heterogenous patient populations.
Detailed comparisons of risk-adjusted patient outcomes for trial and non-trial patients within sites and across multiple sites
Incorporates unique insights from assessment of 146 surgical complications, 32 triggers of avoidable harm, 40 dedicated maternity metrics, Covid-19 mortality and composite metrics
C2-Ai helps pharma companies target and launch drugs faster, and do so at lower cost
UNMET NEEDS:
C2-Ai’s systems can help Pharma companies identify unmet needs and deliver new molecules to market faster and at lower cost.
PATIENT INCLUSION:
Drug trials typically exclude patients with comorbidities because it is too complicated to isolate the effect of these from the impact on the patient of a trial drug or treatment.
RISK ADJUSTMENT:
C2-Ai’s systems manage this complexity by risk-adjusting for each patient’s physiology / comorbidities to calculate the probability of complications by type and risk of mortality. This eliminates the ‘noise’ and complexity due to the variation between patients.
EFFICIENCY:
This means comparing observed patient outcomes with expected outcomes delivers meaningful insights into the efficacy or otherwise of a treatment being trialled, across a far wider population and more quickly.
Transformative but not disruptive systems deliver significant benefits
Fast, and evidence-based insights into unmet needs that might otherwise be missed among a patient population
Larger population trials carried out in parallel (as more patients involved)
Fewer sites needed to hit enrolment target numbers – as more patients per site. Reduces trial complexity and cost.
Faster time to trial, as enrolment can be quicker with broader inclusion criteria and less prohibitive exclusion criteria
Early identification of performance of candidate treatments among a broader patient population means earlier decisions on abandoning of ineffective treatments
Ability to test drugs on true target patient groups (as well as ‘fit and well’ patients) rather than ultimately discovering side effects or other issues such as inefficacy in treating those groups
Ability to re-assign resources earlier from ineffective treatments to ones showing promise
Earlier cessation of trials that would typically continue for longer before being cancelled – saving costs
Earlier launch of treatments.
Awards and recognition in the last 12 months
